Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358060 | 0.90 | CSNK2A2 (0.41) | CSNK2A2TNFTYK2 | |
| SCHEMBL3313265 | 0.87 | CSNK2A2 (0.32) | CSNK2A2TNFKIT | |
| SCHEMBL3313201 | 0.85 | CSNK2A2 (0.47) | CSNK2A2TYK2JAK2KITJAK1 | |
| SCHEMBL2357208 | 0.85 | CSNK2A2 (0.33) | CSNK2A2IDO1TDO2TNFTYK2 | |
| SCHEMBL12013318 | 0.80 | CSNK2A2 (0.46) | CSNK2A2TYK2 | |
| SCHEMBL3318537 | 0.79 | TYK2 (0.37) | CSNK2A2IDO1TDO2TNFGRM5 | |
| SCHEMBL2357319 | 0.79 | KCNH2 (0.44) | CSNK2A2IDO1TDO2GRM5TYK2 | |
| SCHEMBL13644195 | 0.75 | CSNK2A2 (0.42) | CSNK2A2 | |
| SCHEMBL3313894 | 0.73 | PRKCQ (0.39) | TYK2 | |
| SCHEMBL3312315 | 0.72 | CSNK2A2 (0.46) | CSNK2A2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | CSNK2A2 135/4885IDO1 2005/4885TDO2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.